The U.S. Food and Drug Administration (FDA) recently issued several public notifications regarding Medisca L-citrulline product.
Initially, the FDA alerted health care professionals and the public that adverse events were reported in patients who were given L-citrulline distributed by Medisca Inc. L-citrulline is used to treat urea cycle disorders, rare genetic disorders in children.
After testing the product, the FDA notified the public that Medisca is voluntarily recalling certain lots of its L-citrulline product as it does not contain any L-citrulline but rather N-acetyl-leucine, Test results indicated that L-citrulline, lot numbers 95482/A, 95482/B, 95482/C, 95482/D and 96453/A, 96453/B, 96453/C, 96453/D do not contain L-citrulline.
Health care professionals should discontinue dispensing from these lots, contact patients, and return all unused product to Medisca Inc.
For more information, please visit www.fda.gov
The information in this brief report is intended for informational purposes only, and is meant to help users better understand health concerns. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions. Copyright © 2024 NatMed. Commercial distribution or reproduction prohibited. NatMed is the leading provider of high-quality, evidence-based, clinically-relevant information on natural medicine, dietary supplements, herbs, vitamins, minerals, functional foods, diets, complementary practices, CAM modalities, exercises and medical conditions. Monograph sections include interactions with herbs, drugs, foods and labs, contraindications, depletions, dosing, toxicology, adverse effects, pregnancy and lactation data, synonyms, safety and effectiveness.
